Osteoporosis Treatment — Cost, Top Hospitals & Success Rates | MyMedicPlus

Osteoporosis is a skeletal disorder characterised by compromised bone strength — a product of reduced bone mineral density (BMD) and deteriorated bone microarchitecture — that predisposes individuals to fragility fractures from low-energy trauma (such as a fall from standing height or less). Osteoporosis is an enormous global public health burden: approximately 200 million people are affected worldwide; 1 in 2 women and 1 in 5 men over 50 will sustain a fragility fracture in their lifetime. The morbidity and mortality associated with hip fracture in the elderly — with 30-day mortality of approximately 10% and 1-year mortality of 20–30%, and significant disability in survivors — make osteoporosis prevention and treatment a clinical priority.

Bone mineral density is measured by dual-energy X-ray absorptiometry (DEXA scanning), which provides a T-score — the number of standard deviations the patient's BMD deviates from the average peak bone mass of a young adult reference population of the same sex. A T-score between -1.0 and -2.5 is defined as osteopenia; a T-score below -2.5 defines osteoporosis. The absolute fracture risk tool FRAX (Fracture Risk Assessment Tool), developed by the World Health Organisation, integrates BMD with clinical risk factors — including age, sex, prior fragility fracture, glucocorticoid use, rheumatoid arthritis, secondary osteoporosis causes, parental hip fracture history, alcohol use, and current smoking — to calculate a 10-year probability of major osteoporotic fracture and hip fracture. Treatment decisions are guided by FRAX thresholds that vary by country.

Osteoporosis treatment aims to reduce fracture risk through two principal mechanisms: antiresorptive agents (which inhibit osteoclast-mediated bone resorption and preserve or increase BMD) and anabolic agents (which stimulate osteoblast-mediated new bone formation and significantly increase BMD, reserved for severe osteoporosis or those who have failed antiresorptive therapy).

Osteoporosis treatment is indicated for patients with T-score below -2.5 on DEXA scanning, those with a prior fragility fracture (indicating clinical osteoporosis regardless of T-score), and those with a 10-year major osteoporotic fracture risk exceeding the country-specific intervention threshold on FRAX. Postmenopausal osteoporosis — the most common form, driven by oestrogen deficiency accelerating bone resorption — affects approximately 1 in 3 women over 50. Male osteoporosis, underrecognised and undertreated, affects approximately 1 in 5 men over 50, often associated with testosterone deficiency, hypogonadism, or corticosteroid use.

Glucocorticoid-induced osteoporosis (GIOP) is the most common cause of secondary osteoporosis: systemic corticosteroid use (equivalent to prednisolone 7.5 mg or more daily for 3 months or longer) causes rapid bone loss and increases fracture risk — prophylactic bisphosphonate therapy is recommended for all patients requiring prolonged glucocorticoid treatment. Other secondary causes include hyperparathyroidism, hyperthyroidism, hyperprolactinaemia, anorexia nervosa, coeliac disease (causing calcium malabsorption), inflammatory bowel disease, rheumatoid arthritis (both from disease activity and corticosteroid use), and malabsorption states. Vertebral fractures — causing back pain, kyphosis, and height loss — are the most common osteoporotic fracture and are often clinically silent (radiologically evident on spine imaging but without recognised fracture episode).

Pharmacological treatment is recommended for all women over 50 and men over 50 who have experienced a fragility fracture — the prior fracture is in itself sufficient evidence of elevated fracture risk to justify treatment without awaiting DEXA. Postmenopausal women and men over 50 with a T-score below -2.5 (osteoporosis) and a high FRAX risk are candidates for pharmacological intervention. Patients on long-term glucocorticoid therapy should receive preventive bisphosphonate treatment regardless of BMD.

All patients with suspected osteoporosis should undergo investigation to exclude secondary causes — a single laboratory panel including serum calcium, phosphate, albumin, vitamin D (25-OH vitamin D), parathyroid hormone (PTH), renal function, thyroid function, testosterone (in men), serum protein electrophoresis, and urinary calcium excretion screens for the major secondary causes. Adequate calcium (1,000–1,200 mg daily, primarily from dietary sources with supplementation if required) and vitamin D (at least 800–1,000 IU daily, supplemented in those who are deficient — targeting serum 25-OH vitamin D above 50 nmol/L) are prerequisites for osteoporosis pharmacotherapy, as antiresorptive drugs have significantly reduced efficacy in the setting of vitamin D deficiency or hypocalcaemia.

Oral bisphosphonates — alendronate (Fosamax, generic) once weekly, and risedronate once weekly or monthly — are the first-line pharmacological treatment for osteoporosis in most guidelines. They inhibit farnesyl pyrophosphate synthase in osteoclasts, inducing osteoclast apoptosis and reducing bone resorption. Clinical trials demonstrate a 40–50% reduction in vertebral fracture risk and 25–30% reduction in hip fracture risk with alendronate. Intravenous zoledronic acid (5 mg infusion once annually) is more convenient for patients who cannot tolerate or comply with oral bisphosphonates; it reduces hip fracture by approximately 41% (HORIZON trial).

Denosumab (Prolia, 60 mg subcutaneous injection every 6 months) is a monoclonal antibody against RANKL (receptor activator of NF-kB ligand), the key signal for osteoclast activation. It significantly reduces both vertebral and hip fractures and is preferred for patients with severe renal impairment (where bisphosphonates are contraindicated), for postmenopausal women intolerant of bisphosphonates, and for high-fracture-risk patients. Discontinuation of denosumab must be managed carefully — abrupt cessation causes a rapid rebound increase in bone turnover markers and significantly increased vertebral fracture risk; transition to a bisphosphonate is recommended before stopping. Anabolic agents — teriparatide (Forsteo, recombinant PTH 1-34, daily subcutaneous injection for 24 months), abaloparatide, and romosozumab (a sclerostin inhibitor combining anabolic and antiresorptive effects) — provide greater BMD gains than antiresorptive drugs and are reserved for patients with severe osteoporosis (multiple vertebral fractures, T-score below -3.5, or failure of antiresorptive therapy).

Bisphosphonate therapy reduces the relative risk of vertebral fracture by approximately 40–50% and hip fracture by 20–40% in postmenopausal women with osteoporosis — translating to substantial absolute risk reductions in high-risk populations. After hip fracture, prompt secondary prevention treatment (bisphosphonate, calcium, and vitamin D) initiated before discharge or within 3 months reduces subsequent fracture risk by approximately 25%. Fracture liaison services — systematic programmes identifying all fragility fracture patients for secondary prevention assessment — reduce re-fracture rates by 20–40% in healthcare systems where they are implemented.

Anabolic agents (teriparatide, romosozumab) produce substantially larger BMD gains than antiresorptive drugs — lumbar spine BMD increases of 8–14% over 18–24 months with teriparatide, compared to 4–6% with bisphosphonates — and are particularly valuable for patients with severe established osteoporosis and multiple vertebral fractures. The overall effectiveness of osteoporosis treatment is underpinned by adequate calcium and vitamin D; supplementation alone reduces fracture risk by approximately 15–20% in vitamin D-deficient elderly subjects.

Oral bisphosphonates cause oesophageal irritation and gastrointestinal side effects (dyspepsia, reflux) in a minority of patients, which can be minimised by strict administration guidelines (take with a full glass of water, remain upright for 30–60 minutes). Oesophageal ulceration or erosion is rare but serious — patients with active oesophageal disease should use IV zoledronic acid instead. Intravenous zoledronic acid causes an acute phase reaction (flu-like symptoms, fever, myalgia) in up to 30% of patients after the first dose, typically self-limiting within 24–72 hours and preventable with paracetamol pre-medication.

Osteonecrosis of the jaw (ONJ) — a serious complication characterised by exposed jaw bone failing to heal — has a very low risk in patients receiving low-intensity osteoporosis doses (approximately 1 in 10,000–100,000 patients per year on oral bisphosphonates), but a substantially higher risk in patients receiving high doses for malignant hypercalcaemia or bone metastases. Dental assessment before starting bisphosphonate therapy and avoidance of invasive dental procedures during treatment is recommended. Atypical femoral fractures — stress fractures of the femoral shaft associated with long-term bisphosphonate use — have an incidence of approximately 1 in 1,000 patients after 3–5 years of therapy, rising to 1 in 100 after 8–10 years; they cause thigh or groin prodromal pain before complete fracture. Denosumab rebound vertebral fractures after abrupt discontinuation can cause multiple simultaneous vertebral fractures — this serious risk requires systematic transition planning.

Initial biochemical response to antiresorptive therapy is assessed by measuring bone turnover markers (serum CTX — C-terminal telopeptide of type I collagen — for resorption; serum P1NP — procollagen type I N-terminal propeptide — for formation) at baseline and 3–6 months after initiating treatment; a significant reduction in CTX confirms adequate suppression of bone resorption. DEXA scanning is repeated at 2 years to assess BMD response and determine whether the therapeutic goal has been achieved (defined as T-score above -2.5 with no further fractures).

Current guidelines recommend reviewing the need to continue bisphosphonate therapy after 3–5 years (5–7 years for intravenous zoledronic acid), as the risk-benefit ratio of continued treatment may change — particularly the small but increasing risk of atypical femoral fractures with prolonged exposure. A 'bisphosphonate holiday' (pausing treatment for 1–3 years) is considered in lower-risk patients who have been treated for 5 years with no new fractures and BMD above -2.5; treatment is resumed if fractures occur or BMD declines below threshold. Patients with osteoporosis should also receive assessment and treatment for falls risk — a comprehensive falls risk assessment addressing vision, medication review, home hazard assessment, and balance and strength exercises significantly reduces fracture incidence independently of BMD.

Generic oral bisphosphonates (alendronate, risedronate) cost $5–25 per month in most countries and are among the most cost-effective medicines in medicine, given the high cost of hip fracture treatment they prevent. Intravenous zoledronic acid costs $200–500 per annual infusion (generic) in the US. Denosumab (Prolia) costs $1,000–1,500 per 6-monthly injection in the US; newer biosimilar denosumab products are reducing costs substantially in Europe and Asia. Teriparatide (Forsteo) costs $4,000–6,000 per month in the US, making it accessible only through insurance with prior authorisation in most cases.

For patients seeking DEXA scanning or osteoporosis specialist consultation, significant cost differentials exist internationally. DEXA scanning costs $100–250 in the US compared to $20–50 in India and Thailand. Endocrinology or metabolic bone disease specialist consultations cost $200–400 in the US versus $30–80 in India. Intravenous zoledronic acid infusion at an outpatient centre in India costs $80–150 compared to $500–1,500 in the US. Calcium and vitamin D supplementation is universally affordable (under $10 per month globally), making the cornerstone of osteoporosis prevention accessible regardless of income.

Non-pharmacological strategies for osteoporosis prevention and management are essential adjuncts: regular weight-bearing and resistance exercise builds and maintains bone density and muscle strength, reduces falls risk, and provides cardiovascular benefits. Meta-analyses show that exercise programmes reduce fracture incidence by 14% in older women. Calcium-rich diet (dairy products, leafy green vegetables, tofu, fortified foods) provides the building blocks of bone without the potential harms of high-dose calcium supplementation (possible increased cardiovascular risk at doses above 1,500 mg daily).

For postmenopausal women, menopausal hormone therapy (MHT) prevents bone loss and reduces fracture risk — it is an appropriate choice for women with significant menopause symptoms who also have increased fracture risk, combining bone protection with symptom relief, but is not recommended as a first-line osteoporosis-specific treatment solely for fracture prevention. Raloxifene (a selective oestrogen receptor modulator — SERM) reduces vertebral fracture risk similarly to bisphosphonates without hip fracture benefit; it additionally reduces breast cancer risk, making it an attractive choice for postmenopausal women with high breast cancer risk and vertebral osteoporosis. Smoking cessation and reduced alcohol consumption are modifiable lifestyle factors that independently improve bone density and reduce fracture risk.